Phase 1 Study of IMC-CS4, a Monoclonal Antibody Targeted to the CSF-1 Receptor (CSF-1R), in Subjects With Advanced Solid Tumors Refractory to Standard Therapy or for Which No Standard Therapy is Available
||Eli Lilly and Company
||Male and Female Patients
|U.S. Govt. ID:
||Richard Carvajal: 646-317-6041 / firstname.lastname@example.org
The purpose of this study is to see if IMC-CS4 (LY3022855) is safe to give to patients. We want to see how you feel when you are receiving treatment, what effects, good and/or bad, the study drug has on you and your tumor and which may be the best dose.
This study is closed
Richard Carvajal, MD
|Have you been diagnosed with advanced solid tumors?